For this particular study, the 177Lu-labeled nanobody was developed as an alternative radioimmunotherapy treatment of HER2-positive breast cancers, as some cancers showed signs of resistance towards traditional anti-HER2 monoclonal antibodies such as Trastuzumab. Here, ERBB2 is linked to breast cancer.